A monoclonal antibody called panitumumab targets the epidermal growth factor receptor (EGFR) and is used to treat metastatic colorectal cancer, particularly in patients with tumors that are KRAS wild-type. When given intravenously, it prevents the development of cancer cells by obstructing EGFR signaling pathways. Skin rash and low magnesium levels are common side effects; severe allergic reactions and lung problems are examples of major ones. Before starting treatment, KRAS mutation testing is necessary to guarantee efficacy. Panitumumab is sold under the Vectibix brand and is frequently used with other chemotherapeutic drugs